TrialLancet (London, England)2025

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.

Masatoshi Kudo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.